Nkarta, Inc. (NKTX) stock
NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.25+0.04 (+3.31%)
Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%
Nkarta EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Nkarta's EPS for the twelve months ending Jun 30, 2026 was -$1.57. For fiscal 2025 it was -$1.41. The highest annual figure on record is -$1.41 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.41 | – |
| FY2024 | Dec 31, 2024 | -$1.60 | – |
| FY2023 | Dec 31, 2023 | -$2.40 | – |
| FY2022 | Dec 31, 2022 | -$2.61 | – |
| FY2021 | Dec 31, 2021 | -$2.62 | – |
| FY2020 | Dec 31, 2020 | -$5.44 | – |
| FY2019 | Dec 31, 2019 | -$14.41 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.54 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.37 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.37 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.29 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.31 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.43 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.35 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.39 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.34 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.58 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.57 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.52 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.63 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.67 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.58 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.61 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.79 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.69 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.68 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.66 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.59 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.44 | – |
| Q2 FY2020 | Jun 30, 2020 | -$30.06 | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.41 | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.62 | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.75 | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.39 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?